Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma

SIMPLE SUMMARY: Programmed cell death ligand 1 (PD-L1) inhibitors are commonly used in treating advanced-stage urothelial carcinoma. Contrary to evaluating PD-L1 expression in tumor biopsy samples, this study assessed whether PD-L1 expression in circulating tumor cells (CTCs) can be a predictor of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Pei-Jhang, Xu, Ting, Cha, Tai-Lung, Tsai, Yi-Ta, Liu, Shu-Yu, Wu, Sheng-Tang, Meng, En, Tsao, Chih-Wei, Kao, Chien-Chang, Chen, Chin-Li, Sun, Guang-Huan, Yu, Dah-Shyong, Chang, Sun-Yran, Yang, Ming-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301435/
https://www.ncbi.nlm.nih.gov/pubmed/34356529
http://dx.doi.org/10.3390/biology10070674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301435/
https://www.ncbi.nlm.nih.gov/pubmed/34356529
http://dx.doi.org/10.3390/biology10070674

Ejemplares similares